Can-Fite BioPharma

Company Overview

Snapshot

Founded in September 1994 by Ilan Cohn, Can-Fite BioPharma operates with 11–50 employees. The company has raised a total of $113.45 million across 20 funding rounds from 2 investors. A significant milestone for the company was securing an Australian patent for its obesity drug Namodenoson in November 2024.

Business overview

Can-Fite BioPharma is an Israeli biopharmaceutical company focused on the discovery and clinical development of proprietary drug candidates. The company's core technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in inflammatory, cancer, and other pathological cells. Can-Fite's compounds bind to A3AR to deregulate NF-kB and Wnt signal transduction pathways, producing anti-inflammatory and anticancer effects. Its pipeline includes drugs like Piclidenoson (CF101), Namodenoson (CF102), and CF602, addressing inflammatory, liver, metabolic, and rare genetic diseases, as well as oncology. The company serves global markets within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In September 2024, Can-Fite BioPharma announced a projected income of $325 million over the next 10 years following Vetbiolix's exercise of its option and licensing of Piclidenoson for veterinary osteoarthritis. This development signals strong commercial validation for Can-Fite's drug pipeline and indicates potential for significant long-term revenue generation from its intellectual property in the animal health market.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Can-Fite BioPharma?

In October 2024, the FDA granted Orphan Drug Designation to Can-Fite’s Namodenoson for pancreatic cancer, recognizing its potential to treat a rare and serious condition.

When did Can-Fite BioPharma become publicly traded on the NYSE?

Can-Fite BioPharma became publicly traded on the NYSE in July 2025.

What was the outcome of Vetbiolix exercising its option for Piclidenoson?

In September 2024, Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, which is projected to generate $325 million in income for Can-Fite over the next 10 years.

Has Can-Fite BioPharma received regulatory authorization for its pancreatic carcinoma study in Israel?

Yes, in September 2024, Can-Fite's Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson received regulatory authorization from the Israeli Ministry of Health.

What was a key development regarding Can-Fite's anti-obesity drug Namodenoson?

In November 2024, Can-Fite BioPharma secured an Australian patent for its anti-obesity drug Namodenoson, following a patent allowance in the same month.